Thirty-one percent of Americans are hypertensive, 30% are prehypertensive, and approximately 20% are hypertensive yet unaware of their status.^[@CIT0001],[@CIT0002]^ Only 47% of those with hypertension are adequately controlled.^[@CIT0001]^ Prior research shows that diet and lifestyle modifications, including physical activity, sodium reduction, and fish oil supplementation, can reduce blood pressure (BP), enhance antihypertensive drug efficacy, and decrease cardiovascular disease (CVD) risk.^[@CIT0003]^

The active ingredients in fish oil considered responsible for its antihypertensive effect are the long-chain omega-3 fatty acids eicosapentaenoic acid (EPA; 20:5 n-3) and docosahexaenoic acid (DHA; 22:6 n-3). Although previous meta-analyses of fish oil supplementation and BP have been published,^[@CIT0004]^ none have been designed with inclusion criteria sufficient to examine the extensive scope of literature available in this active area of investigation. For example, the most recently published meta-analysis excluded trials that examined food sources of EPA and DHA (herein referred to as EPA+DHA) and those that were less than 8 weeks in duration.^[@CIT0007]^ Therefore, our main objective was to update the state of the science by conducting the most comprehensive meta-analysis of its kind of randomized controlled trials (RCTs) that examined EPA+DHA in relation to BP.

METHODS {#s1}
=======

Literature review {#s2}
-----------------

A comprehensive literature search was conducted by the University of Colorado Denver Health Science Library using Ovid/Medline, Embase, and the Cochrane Library. A PubMed search was performed in February 2013 to identify any publications not yet indexed by Ovid/Medline. Literature searches covered studies published from 1946 through February 2013 and published in all languages. Level 1 screening included review of all titles and/or abstracts. Full-text publications of any studies not eliminated at level 1 were retrieved for complete review at level 2 screening. Supplementary literature searches included examining the reference lists of all relevant studies, pertinent review articles, and meta-analyses.

Eligibility criteria for study selection {#s3}
----------------------------------------

Included studies were RCTs that examined the effect of EPA+DHA on BP in nonhospitalized adults (aged ≥18 years). Eligible outcomes were systolic and diastolic BP values (SBP and DBP, respectively). The exclusion criteria in this review were as follows:

1.  Hypertensive subjects treated with BP-lowering medications;

2.  Less than 3-week treatment duration;

3.  Crossover RCTs with less than a 4-week washout period between treatments;

4.  Studies that did not specify the amount of EPA+DHA provided or without required data to be used meta-analytically (all authors of otherwise eligible studies were contacted for missing data); and

5.  Studies conducted in populations not representative of the general adult population, including pregnant and nursing women and individuals with preexisting CVD or significant disease process (e.g., renal disease or cancer) or secondary hypertension.

Data extraction and quality assessment {#s4}
--------------------------------------

The following qualitative and quantitative information was extracted from all RCTs: publication year, population demographic characteristics, geographic location, baseline hypertensive status, other relevant baseline health characteristics, medication use, sample size, the specific dose of EPA+DHA, the type of food or supplement, outcome assessment method, and means and SDs for BP outcomes.

Data synthesis {#s5}
--------------

Random-effects meta-analysis models were used to calculate weighted group mean differences (postintervention minus preintervention), 95% confidence intervals (CIs), and corresponding *P* values for heterogeneity between the EPA+DHA group and the placebo group. The weight of each study was based on the inverse of the variance, which is a measure that accounts for the sample size in each group. The macro-level models included data on all subjects at all dose levels. Subgroup analyses were conducted to identify potential sources of heterogeneity or between-study variability and to estimate the effect of EPA+DHA according to key study characteristics. Categorical dose--response analyses were performed to discern potential patterns or thresholds of effect. Sensitivity and influence analyses were conducted by evaluating the impact of adding or removing studies based on important study characteristics and outlier status. The relative weight of each study was appreciated for each meta-analysis model to determine the influence that each study had on the overall summary effect. The presence of publication bias was assessed visually by examining a funnel plot measuring the SE as a function of effect size, as well as performing Egger's regression method and the Duval and Tweedie imputation method.^[@CIT0008]^ All analyses were performed using Comprehensive Meta-Analysis (version 2.2.046; Biostat, Englewood, NJ).

RESULTS {#s6}
=======

Study Characteristics {#s7}
---------------------

A flow diagram of the search strategy, including reasons for exclusion, is shown in [Figure 1](#F1){ref-type="fig"}. A total of 70 RCTs^[@CIT0009]^ met all eligibility criteria and were included in the meta-analysis. The main study characteristics are shown in [Table 1](#T1){ref-type="table"} (hypertensive populations) and [Table 2](#T2){ref-type="table"} (normotensive populations, with 1 prehypertensive population).^[@CIT0017]^ Ramel *et al*.^[@CIT0063]^ examined hypertensive and normotensive subjects combined; these data are included in [Table 1](#T1){ref-type="table"} but were not meta-analyzed in the subgroup analyses by hypertension status. Approximately 40% of the included RCTs were conducted in North America, with the remaining distributed primarily between Nordic countries (20%), European countries other than the Nordic countries (27%), and Australia (13%). The mean study duration was 69 days, the mean EPA+DHA dose was 3.8g/day, and sources of EPA+DHA included different types of seafood, EPA+DHA--fortified foods, fish oil, algal oil, and purified ethyl esters. Olive oil was the most commonly used placebo, with the remainder consisting predominately of other vegetable oils (e.g., safflower, corn, and sunflower oils).

![Flow diagram of literature search and selection of randomized controlled trials (RCTs) for meta-analysis of eicosapentaenoic and docosahexaenoic acids (EPA+DHA) and blood pressure.](ajhype_hpu024_f0001){#F1}

###### 

Characteristics of the randomized controlled trials in hypertensive study populations^a^

  First author   Year   Country                   Age, y^b^   Sex, M/F^c^   Duration, d   Intervention regimen   Control                      
  -------------- ------ ------------------------- ----------- ------------- ------------- ---------------------- --------- ----- ----- ------ ---------------------------
  Bonaa^14^      1990   Norway                    20--61      156 (M+F)     70            Fish oil (EE)          6         1.8   3.2   5.1    Corn oil
  Hill^38^       2007   Australia                 25--65      28/53         84            Fish oil               6         1.6   0.4   1.9    Sunflower oil
  Hughes^39^     1990   United States             NR          26/0          30            Fish oil               10        1.5   3.5   5.0    Wheat germ oil
  Knapp^41^      1989   United States             30--71      36/0          28            Fish oil               50        6.0   9.0   15.0   Safflower oil
                                                                                                                 10        1.2   1.8   3.0    Mixed vegetable oils
  Landmark^42^   1993   Norway                    33--64      18/0          28            Fish oil (EE)          10        2.8   1.8   4.8    Olive oil
  Levinson^43^   1990   United States             18--75      17 (M+F)      42            Fish oil               50        6.0   9.0   15.0   Vegetable oil
  Meland^48^     1989   Norway                    26--66      40/0          42            Fish oil               20        2.4   3.6   6.4    Olive + corn oil
  Mundal^54^     1993   Norway                    33--64      18/0          28            Fish oil               ―         2.8   1.8   4.6    Olive oil
  Passfall^60^   1993   Germany                   40--61      4/6           42            Fish oil               9         0.9   1.3   2.2    Olive oil
  Prisco^61^     1998   Italy                     33--57      32/0          120           Fish oil (EE)          4         1.4   2.0   3.6    Olive oil
  Radack^62^     1991   United States             ≥ 18        19/14         84            Fish oil               6         0.8   1.2   2.0    Safflower oil
  Ramel^63,f^    2010   Iceland, Spain, Ireland   20--40      138/186       56            Fish oil               6         ―     ―     2.1    Sunflower oil
                                                                                          Cod                    64        ―     ―     1.3    
                                                                                          Salmon                 64        ―     ―     0.3    
  Sagara^65^     2011   United Kingdom            45--59      38/0          35            DHA-enriched bread     2         2.0   0.0   2.0    Olive oil--enriched bread
  Steiner^69^    1989   Switzerland               44 (13)     17/11         28            Fish oil               4         0.5   1.1   2.0    Salad oil
  Toft^71^       1995   Norway                    20--61      50/28         112           Fish oil (EE)          4         ―     ―     3.4    Corn oil
  Wang^77^       2008   China                     42 (3)      14/7          56            Fish oil               3         0.4   0.5   0.9    Vegetable oil

Abbreviations: DHA, docosahexaenoic acid; EE, ethyl esters; EPA, eicosapentaenoic acid; F, female; M, male; NR, not reported.

^a^ Two study populations (Hughes *et al*. 1990^39^ and Steiner *et al*. 1989^69^) were stratified by hypertensive status; therefore, only study

characteristics for hypertensives are shown here.

^b^ Mean (SD) is shown when range was not provided.

^c^ The total sample size is shown plus M+F to indicate both men and women were included when the distribution by sex was not provided.

^d^ Dose of entire fish oil supplement or food.

^e^ May include small amounts of docosapentaenoic acid.

###### 

Characteristics of the randomized controlled trials in normotensive study populations^a^f Not included in hypertensive-only meta-analysis because only a portion of the population (32%) was hypertensive

  First author          Year   Country                Age, y^b^   Sex, M / F^c^   Duration, d   Intervention regimen                              Control                     
  --------------------- ------ ---------------------- ----------- --------------- ------------- ------------------------------------------------- --------- ----- ----- ----- -------------------------------------------------------------
  Armstong^10^          2012   United States          20--59      35/81           42            Fish oil (EE)                                     5         1.0   2.0   3.0   Corn + soy oil
  Atar^11^              2012   Iran                   45--65      0/78            56            Fish oil                                          2         0.5   0.7   1.2   Cornstarch
  Bach^12^              1989   United States          31 (9)      16/14           35            Fish oil                                          6         1.4   1.1   2.5   Fractionated coconut oil
  Barcelo-Coblijn^13^   2008   Canada                 36--43      50/3            84            Fish oil                                          0.6       0.1   0.3   0.4   Sunflower oil
                                                                                                                                                  1.2       0.3   0.5   0.8   
  Browning^15^          2007   United Kingdom         \< 50       0/33            84            Fish oil                                          ―         2.9   1.3   4.2   Oleic + linoleic acid oil
  Buckley^16^           2009   Australia              22 (1)      25/0            35            Fish oil                                          6         1.6   0.4   1.9   Sunflower oil
  Carter^17,f^          2012   United States          24 (2)      18/20           56            Fish oil                                          9         1.1   1.6   2.7   Olive oil
  Cazzola^18^           2007   Italy                  18--42      100/0           84            Fish oil                                          3         0.3   1.4   1.6   Corn oil
                                                                                                                                                  6         0.5   2.7   3.2   
                                                                                                                                                  9         0.8   4.1   4.9   
  Chin^19^              1993   Australia              18--32      29/0            28            Fish oil                                          5         0.6   0.9   1.5   Palm + safflower + olive oil
                                                                                                                                                  10        1.2   1.8   2.9   
                                                                                                                                                  20        2.3   3.6   5.9   
  Cobiac^20^            1991   Australia              30--60      31/0            35            Salmon + sardines                                 164       3.0   1.5   4.5   Mixed vegetable oil
                                                                                                Fish oil                                          15        1.6   3.0   4.6   
  Conquer^21^           1999   Canada                 30 (2)      19/0            42            Seal oil                                          20        1.7   1.3   3.8   Vegetable oil
  Croset^22^            1990   France                 86 (4)      NR              60            Fish oil (EE)                                     0.1       0.0   0.1   0.1   Placebo oil (NFS)
  Demke^23^             1988   United States          18--60      8/23            28            Fish oil                                          5         ―     ―     1.7   Safflower oil
  Derosa^25^            2009   Italy                  ≥18         164/169         180           Fish oil (EE)                                     3         1.5   0.9   2.4   Sucrose, mannitol and mineral salts
  Derosa^24^            2012   Italy                  18--75      82/85           180           Fish oil (EE)                                     3         1.4   1.2   2.6   Sucrose, mannitol and mineral salts
  Deslypere^26^         1992   Belgium                21--90      58/0            365           Fish oil                                          3         0.2   0.8   1.1   Olive oil
                                                                                                                                                  6         0.3   1.6   2.1   
                                                                                                                                                  9         0.5   2.4   3.2   
  Dewell^27^            2011   United States          50 (10)     64/36           60            Fish oil                                          2         0.5   0.7   1.2   Soybean oil
                                                                                                                                                  6         1.5   2.1   3.6   
  Dyerberg^28^          2004   Denmark                20--60      87/0            56            Fish oil                                          12        1.3   2.0   3.3   Palm oil
  Finnegan^29^          2003   United Kingdom         25--72      87/63           120           EPA+DHA-enriched margarine                        25        0.3   0.2   0.5   Margarine (sunflower + safflower oil-based)
                                                                                                EPA+DHA--enriched margarine + fish oil capsules   28        ―     ―     1.3   Margarine + capsules (both sunflower + safflower oil-based)
  Flaten^30^            1990   Norway                 35--45      56/0            42            Fish oil                                          14        2.9   3.6   6.8   Olive Oil
  Geelen^31^            2003   Nether-lands           50--70      36/38           84            Fish oil                                          3.5       0.6   0.7   1.3   Sunflower oil
  Ginty^32^             2012   United States          NR          8/26            21            Fish oil                                          ―         0.4   1.0   1.4   Corn oil
  Grimsgaard^33^        1998   Norway                 36--56      224/0           49            Fish oil (EE)                                     4         0.0   4.0   4.0   Corn oil
                                                                                                                                                  4         4.0   0.0   4.0   
  Gustafsson^34^        1996   Sweden                 48 (9)      24 (M+F)        21            EPA+DHA-enriched food products                    57        ―     ―     3.2   Sunflower-enriched food products
  Hallund^35^           2010   Denmark                40--70      45/0            56            Marine trout                                      150       2.0   0.9   3.2   Chicken
  Harris^36^            2008   United States          21--70      14 /19          112           Fish oil (EE)                                     23        0.0   1.0   1.0   Soybean oil
  Hellsten^37^          1993   Sweden                 30--60      40 (M+F)        150           Cod liver oil                                     6         ―     ―     2.0   Corn oil
  Hughes^39^            1990   United States          NR          26/0            30            Fish oil                                          10        1.5   3.5   5.0   Wheat germ oil
  Kelley^40^            2007   United States          54 (2)      34/0            90            Fish oil                                          7.5       3.0   ―     3.0   Olive oil
  Lindqvist^78^         2009   Sweden                 35--60      35/0            42            Baked herring                                     150       ―     ―     1.2   Baked lean pork + chicken
  Lofgren^44^           1993   United States          40--60      23/0            84            Fish oil                                          20        2.4   3.6   6.0   Safflower oil
  Mackness^45^          1994   7 European countries   30--71      55/24           98            Fish oil                                          4         ―     ―     3.4   Corn oil
  Maki^46^              2009   United States          35--64      8/42            28            Krill oil                                         2         0.1   0.2   0.3   Olive oil
                                                                                                Fish oil                                          2         0.2   0.2   0.4   
  McVeigh^47^           1994   Ireland                45--61      16/4            42            Fish oil                                          10        1.2   1.8   3.0   Olive oil
  Mills^50^             1989   Canada                 22--34      20/0            28            Fish oil                                          9         1.0   1.6   2.6   Olive oil
  Mills^49^             1990   Canada                 19--31      29/0            28            Fish oil                                          4.5       0.5   0.8   1.3   Safflower Oil
  Monahan^51^           2004   United States          18--35      10/8            30            Fish oil                                          10        2.0   3.0   5.0   Olive Oil
  Mori^52^              1999   Australia              20--65      56/0            42            Fish oil (EE)                                     4         0.0   3.8   3.8   Olive oil
                                                                                                                                                  4         3.7   0.0   3.7   
  Mortensen^53^         1983   Denmark                25--40      20/0            28            Fish oil                                          10        0.5   0.8   1.4   Vegetable oil
  Murphy^55^            2007   Australia              20--65      35/39           190           EPA+DHA--enriched foods                           ―         ―     ―     1.0   Same foods, without DHA+EPA enrichment
  Neff^56^              2010   United States          18--65      15/21           112           Algal oil                                         5         2.0   0.0   2.0   Corn + soybean oil
  Nestel^57^            2002   United States          40--69      21/17           49            Fish oil (EE)                                     4         0.1   3.0   3.1   Olive oil
                                                                                                                                                  4         2.8   0.2   3.5   
  Nordoy^58^            2001   Norway                 28--61      32/10           35            Fish oil (EE)                                     2         0.8   0.9   1.7   Corn oil
  Noreen^59^            2012   United States          19--55      14/26           42            Fish oil                                          4         1.0   1.8   3.1   Safflower oil
  Ryu^64^               1990   United States          20--39      20/0            28            Fish oil                                          6         0.9   2.1   3.0   Wheat germ oil
  Sanders^66^           2006   United Kingdom         33 (13)     39/40           28            Fish oil                                          4         1.5   0.0   1.5   Olive oil
  Sjoberg^67^           2010   Australia              53 (17)     17/16           84            Fish oil                                          2         0.5   0.1   0.7   Sunola oil
                                                                                                                                                  4         1.0   0.2   1.3   
                                                                                                                                                  6         1.6   0.3   2.0   
  Stark^68^             2004   Canada                 45--70      0/32            28            Fish oil                                          6         2.8   0.0   2.8   Corn + soy oil
  Steiner^69^           1989   Switzer-land           44 (13)     17/11           28            Fish oil                                          4         0.5   1.1   2.0   Salad oil
  Theobald^70^          2007   United Kingdom         45--65      20/19           90            Fish oil                                          1.5       0.7   0.0   0.7   Olive oil
  THPCRG^9^             1992   United States          30--54      245/105         180           Fish oil                                          6         1.0   1.4   3.6   Olive oil or other placebo
  Vakhapova^72^         2011   Israel                 50--90      67/63           105           Fish oil                                          3         0.0   0.0   0.0   Cellulose
  Vandongen^73^         1993   Australia              30--60      51/0            84            Fish oil                                          6         0.9   1.3   2.3   Olive + palm + safflower oils
                                                                                                                                                  12        1.7   2.6   4.7   
  Vericel^74^           1999   France                 70--83      6/14            42            Fish oil                                          0.6       0.2   0.0   0.2   Sunflower oil
  von Houwelingen^75^   1987   Nether-lands           20--45      82/0            42            Mackarel paste                                    135       3.0   1.7   4.7   Meat paste
  Walser^76^            2008   United States          20--51      14/7            42            Fish oil                                          10        2.0   3.0   5.0   Safflower oil

Abbreviations: DHA, docosahexaenoic acid; EE, ethyl esters; EPA, eicosapentaenoic acid; NFS, not further specified; NR, not reported; THPCRG, Trials of Hypertension Prevention Collaborative Research Group.

^a^ Two study populations (Hughes *et al*. ^39^ and Steiner *et al*. ^69^) were stratified by hypertensive status; therefore, only study

characteristics for normotensives are shown here.

^b^ Mean (SD) is shown when range was not provided.

^c^ The total sample size is shown plus M+F to indicate both men and women were included when the distribution by sex was not provided.

^d^ Dose of entire fish oil supplement or food.

^e^ May include small amounts of docosapentaenoic acid.

^f^ Population includes normotensive and prehypertensive subjects.

Results from meta-analysis {#s8}
--------------------------

Meta-analysis results for all analyses are reported in [Table 3](#T3){ref-type="table"}, and results for selected analyses are illustrated in [Figures 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"} and [Supplementary Figures S1](http://ajh.oxfordjournals.org/lookup/suppl/doi:10.1093/ajh/hpu024/-/DC1) and [S2](http://ajh.oxfordjournals.org/lookup/suppl/doi:10.1093/ajh/hpu024/-/DC1).

###### 

Summary of meta-analysis results

  Model                      No. of data points   WGMD    Lower 95% CI   Upper 95% CI   *P* value for heterogeneity
  -------------------------- -------------------- ------- -------------- -------------- -----------------------------
  Systolic blood pressure                                                               
   All studies^a^            93                   −1.52   −2.25          −0.79          0.001
   Supplement only           82                   −1.75   −2.55          −0.94          0.001
   Food only                 11                   0.10    −1.31          1.50           0.50
   US studies                25                   −1.78   −3.33          −0.23          0.03
   Non-US studies            68                   −1.33   −2.16          −0.50          0.007
   Duration ≥60 days         41                   −1.63   −2.67          −0.59          0.08
   Dose 0 to \<1 g           12                   −2.38   −5.14          0.38           0.009
   Dose 1 to \<2 g           19                   −1.81   −3.59          −0.03          0.47
   Dose 2 to \<3 g           18                   −0.21   −1.85          1.43           0.007
   Dose 3 to \<4 g           22                   −3.85   −5.55          −2.15          0.05
   Dose 4 to \<5 g           11                   −0.86   −1.84          0.13           0.97
   Dose ≥5 g                 10                   −0.36   −2.95          2.23           0.17
   Hypertensive subjects     15                   −4.51   −6.12          −2.83          0.72
   Normotensive subjects     73                   −1.25   −2.05          −0.46          0.01
   EPA only                  7                    −4.61   −8.35          −0.86          0.01
   DHA only                  8                    −1.27   −3.37          0.84           0.28
   Ethyl ester               15                   −2.24   −3.72          −0.76          0.002
   Other marine oils         67                   −1.45   −2.39          −0.50          0.007
  Diastolic blood pressure                                                              
   All studies^a^            92                   −0.99   −1.54          −0.44          0.00
   Supplement only           81                   −1.11   −1.72          −0.50          0.00
   Food only                 11                   −0.38   −1.46          0.70           0.75
   US studies                24                   −1.35   −2.48          −0.21          0.02
   Non-US studies            68                   −0.88   −1.52          −0.25          0.00
   Duration ≥60 days         41                   −0.95   −1.56          −0.34          0.31
   Dose 0 to \<1 g           10                   0.04    −1.48          1.56           0.78
   Dose 1 to \<2 g           21                   0.40    −1.10          1.91           0.001
   Dose 2 to \<3 g           18                   −1.09   −2.08          −0.11          0.16
   Dose 3 to \<4 g           22                   −1.86   −2.67          −1.06          0.36
   Dose 4 to \<5 g           11                   −0.59   −1.37          0.19           0.94
   Dose ≥5 g                 10                   −1.97   −3.96          0.02           0.06
   Hypertensive subjects     15                   −3.05   −4.35          −1.74          0.17
   Normotensive subjects     72                   −0.62   −1.22          −0.02          0.002
   EPA only                  5                    −0.81   −1.99          −0.37          0.55
   DHA only                  8                    −0.84   −2.29          0.62           0.32
   Ethyl ester               16                   −0.80   −1.49          −0.11          0.28
   Other marine oils         64                   −1.20   −2.02          −0.37          0.00

Abbreviations: CI, confidence interval; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; WGMD, weighted group mean difference.

^a^ Includes all studies, regardless of dose, duration, region, hypertensive status, and source of EPA+DHA (supplement or food).

![Results from meta-analyses of randomized controlled trials examining eicosapentaenoic and docosahexaenoic acids (EPA+DHA) provision and (**a**) systolic blood pressure and (**b**) diastolic blood pressure among hypertensive subjects. The squares represent average change in blood pressure in individual randomized controlled trials, or individual trial strata, with 95% confidence intervals (CIs). The diamond represents the pooled summary estimate. Knapp (a) is a higher-dose subgroup, and Knapp (b) is a lower-dose subgroup.](ajhype_hpu024_f0002){#F2}

![Results from meta-analyses of randomized controlled trials examining eicosapentaenoic and docosahexaenoic acids (EPA+DHA) and (**a**) systolic blood pressure and (**b**) diastolic blood pressure by EPA+DHA dose category. The circle represents the pooled summary estimate across all studies within each dose category, with 95% confidence intervals (CIs). n indicates the number of data points in each dose category, which may be greater than the number of individual studies.](ajhype_hpu024_f0003){#F3}

In the overall meta-analysis model of 93 data points from 70 RCTs, SBP decreased by 1.52mm Hg (95% CI = [**−**]{.smallcaps}2.25 to [**−**]{.smallcaps}0.79) and DBP by 0.99mm Hg (95% CI = [**−**]{.smallcaps}1.54 to [**−**]{.smallcaps}0.44), compared with placebo, after EPA+DHA provision ([Table 3](#T3){ref-type="table"}; [Supplementary Figures S1](http://ajh.oxfordjournals.org/lookup/suppl/doi:10.1093/ajh/hpu024/-/DC1) and [S2](http://ajh.oxfordjournals.org/lookup/suppl/doi:10.1093/ajh/hpu024/-/DC1)). Studies with multiple entries in the meta-analysis models reflect results presented separately by the authors for different subgroups (e.g., low-dose and high-dose EPA+DHA). In the meta-analysis of hypertensive subjects, significant reductions in SBP ([**−**]{.smallcaps}4.51mm Hg; 95% CI = [**−**]{.smallcaps}6.12 to [**−**]{.smallcaps}2.83) and DBP ([**−**]{.smallcaps}3.05mm Hg; 95% CI = [**−**]{.smallcaps}4.35 to [**−**]{.smallcaps}1.74) were observed ([Figure 2](#F2){ref-type="fig"}). The meta-analysis of studies among normotensive subjects also found a significant reduction of SBP ([**−**]{.smallcaps}1.25mm Hg; 95% CI = [**−**]{.smallcaps}2.05 to [**−**]{.smallcaps}0.46) and DBP ([**−**]{.smallcaps}0.62mm Hg; 95% CI = [**−**]{.smallcaps}1.22 to [**−**]{.smallcaps}0.02) ([Table 3](#T3){ref-type="table"}). The summary estimates were modified by source of EPA+ DHA and by study region ([Table 3](#T3){ref-type="table"}). In the meta-analysis of supplement-only studies, SBP decreased by 1.75mm Hg (95% CI = [**−**]{.smallcaps}2.55 to [**−**]{.smallcaps}0.94) and DBP by 1.11 (95% CI = [**−**]{.smallcaps}1.72 to [**−**]{.smallcaps}0.50) after EPA+DHA provision, compared with placebo. Among US-only studies, reductions of 1.78mm Hg (95% CI = [**−**]{.smallcaps}3.33 to [**−**]{.smallcaps}0.23) in SBP and 1.35mm Hg (95% CI = [**−**]{.smallcaps}2.48 to [**−**]{.smallcaps}0.21) in DBP were observed. Because relatively few studies evaluated EPA+DHA as individual fatty acids, there was insufficient statistical power to detect a meaningful difference between EPA and DHA separately on lowering either SBP or DBP.

The subgroup analyses by dose are depicted in [Figure 3](#F3){ref-type="fig"}. There was no clear pattern of dose--response between EPA+DHA and SBP. Significant reductions were observed with doses of 1 to \<2g/d ([**−**]{.smallcaps}1.81; 95% CI = [**−**]{.smallcaps}3.59 to [**−**]{.smallcaps}0.03) and 3 to \<4g/d ([**−**]{.smallcaps}3.85; 95% CI = [**−**]{.smallcaps}5.55 to [**−**]{.smallcaps}2.15). No apparent effect on DBP was observed for dose levels \<2g/day, whereas significant reductions were observed for 2 to \<3g/day ([**−**]{.smallcaps}1.09; 95% CI = [**−**]{.smallcaps}2.08 to [**−**]{.smallcaps}0.11) and 3 to \<4g/day ([**−**]{.smallcaps}1.86; 95% CI = [**−**]{.smallcaps}2.67 to [**−**]{.smallcaps}1.06).

An examination of potential publication bias indicated a modest proclivity for published studies that found a significant SBP reduction with EPA+DHA provision ([Supplementary Figure S3](http://ajh.oxfordjournals.org/lookup/suppl/doi:10.1093/ajh/hpu024/-/DC1)). There was a slight indication of publication bias with a proclivity for publication of results that showed a significant DBP reduction with EPA+DHA provision, which was modified by study region. Non-US studies were more likely to publish findings showing DBP reduction with EPA+DHA provision, whereas US studies were more likely to publish null findings or an increase in DBP with EPA+DHA provision.

DISCUSSION {#s9}
==========

This meta-analysis of RCTs that examined EPA+DHA provision and BP provides the most comprehensive quantitative summary of the evidence to date. Before this meta-analysis, the most recent published meta-analysis^[@CIT0007]^ excluded studies \<8 weeks in duration and those that examined food sources of EPA+DHA. By liberalizing the duration restriction to 3 weeks, including RCTs conducted with EPA+DHA--rich and --fortified foods, and capturing recent RCTs published in the past 2 years, our meta-analysis evaluated an additional 53 studies not included by Campbell *et al*.^[@CIT0007]^ The considerably larger volume of studies enhanced the statistical power to perform important subgroup analyses by factors such as dose, geographic region, hypertensive status, and source of EPA+DHA.

The results from our analysis demonstrate that EPA+DHA are as effective, and in some cases more effective, than other lifestyle-related interventions, including increasing physical activity and restricting alcohol and sodium,^[@CIT0079]^ for lowering BP among hypertensive populations not taking antihypertensive medication. These results are consistent with findings from Campbell *et al*.^[@CIT0007]^ as well as other earlier meta-analyses.^[@CIT0080],[@CIT0081]^ Lowered systemic vascular resistance through changes in endothelial function is considered a primary mechanism by which EPA+DHA may lower BP.^[@CIT0082]^ Recent systematic reviews and a meta-analysis of RCTs found improved endothelial function in response to EPA+DHA, particularly among patients with risk factors for CVD, including hypertension, but not consistently among healthy young and middle-aged subjects.^[@CIT0083],[@CIT0084]^ This observation may explain the greater response of unmedicated hypertensive subjects when compared with normotensive subjects in our meta-analysis.

The reductions in BP observed in this analysis are not only statistically significant but also are clinically meaningful. Among adults, SBP rises by approximately 0.6mm Hg per year; among those aged ≥50 years, the lifetime risk of hypertension is 90%.^[@CIT0085]^ Furthermore, only 1mm Hg SBP separates each stage of hypertension. The statistically significant reduction in SBP of 1.25mm Hg noted among normotensive individuals in our analysis would represent a delay of age-related SBP increase by 2 years and progression from prehypertensive to hypertensive status. The 4.51mm Hg decrease observed among hypertensive populations not taking antihypertensive medication could prevent an individual from requiring medication to control their hypertension or could help maintain an individual in a lower stage of progressive hypertension. Lowered systemic vascular resistance and BP can reduce risk of coronary plaque rupture, stroke, and complications of stroke, including related cognitive decline, thus improving clinical outcomes for higher-risk populations.^[@CIT0082]^

Overall, there was no clear discernible pattern of a dose--response effect for EPA+DHA on BP, which is similar to findings from past meta-analyses.^[@CIT0007],[@CIT0081],[@CIT0086]^ Although less data are available that examine EPA+DHA--rich or --fortified food and BP outcomes (n = 8 studies in this meta-analysis), EPA+DHA--rich or --fortified foods were less effective than supplements with regards to lowering BP. It is important to note, however, that there are barriers to frequent fish consumption, which may explain in part the discrepant findings between food and supplement studies. Among the general population, barriers to frequent fish consumption include dislike of taste, unpleasant smell, and "concerns about bones."^[@CIT0087],[@CIT0088]^ Five of the 8 food studies in the current meta-analysis required daily consumption of oily fish, including sardines, mackerel, and salmon. Although compliance was not routinely reported among all food studies, von Houwelingen *et al.*,^[@CIT0075]^ who provided subjects with mackerel, reported compliance of only 78%. In addition, the researchers noted that a tendency for compliance decreased over the course of the study, as assessed by urinary lithium excretion. Only 3 studies of EPA+DHA--fortified foods (e.g., margarine and bread)^[@CIT0029],[@CIT0055],[@CIT0065]^ were identified for inclusion in our meta-analysis, which challenges efforts to fully investigate the role of these EPA+DHA sources as part of an overall healthy dietary pattern.

Collectively, the evidence from RCTs indicates that provision of ≥2g/d EPA+DHA may reduce both SBP and DBP, with the strongest benefits observed among hypertensive individuals who are not on antihypertensive medication. In addition, a lower dose (between 1 and 2g/d) may reduce SBP but not DBP. From a clinical and public health perspective, provision of EPA+DHA may lower BP and ultimately reduce the incidence of associated chronic diseases.
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Supplementary materials are available at *American Journal of Hypertension* ([http://ajh.oxfordjournals.org](http://ajh.oxfordjournals.org/lookup/suppl/doi:10.1093/ajh/hpu024/-/DC1)).
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